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AbstractThe study aims at demonstrating the efficiency of phytotherapy in macroprolactinoma downsizing. Thecomparison of phytotherapeutic (PT) efficiency leant on medical records submitted by the patients prior to the PTlaunch, indicating the diagnosis established based on the outcome of the nuclear magnetic resonance imaging (NMRI)and/or computed tomography (CT) of the affected site and bringing the results of field-of-vision examination andhormonal status determination. The insight into the documentation in reference provided the information on tumoursize and prolactin levels. The data in reference were compared against medical records submitted followingphytotherapy completion. This study brings the results of a five-year investigation into the influence of phytotherapyon the size of macroprolactinomas. In patients responsive to this kind of treatment, tumour regression was witnessedwithin 6 months of herbal remedy use. A substantial tumour downsizing was accompanied by vision restitution;namely, in a number of cases, sight impairments are the first indicators of tumour presence. The basic parametersused for phytotherapeutic efficiency estimation and follow-up were the size of the tumour and the state of the field-of-vision, established both prior to and following phytotherapy. The results of the study presented herein unequivocallydemonstrated the efficiency of phytotherapy in macroprolactinoma tumour mass downsizing, providing thereforesolid grounds for the implementation of phytotherapy as a novel treatment modality of this tumour cluster.
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IntroductionProlactinomas are the most common functional tumours of the pituitary gland, representing an approximate45-percent share of the total hormone-releasing tumour pool (Horvath and Kovacs, 1992). Nearly 90% ofprolactinomas are of the lactotrophic origin, while the remaining 10% are mixed tumours built up of both lactotrophicand somatotrophic cells characterised by enhanced prolactin and growth factor release (Scheithauer et al, 1986).Prolactinomas mutually differ in their size and secretion activity. Based on their size, they can be divided into micro-and macroprolactinomas. Microprolactiomas grow slowly, up to only a few millimetres in size and are usuallydistinctive and not prone to grow further (Mah and Webster, 2001; Guyton and Hall, 2003). In the majority of thediseased, macroprolactinomas grow over 10 mm in size; their growth is mostly rapid and expansive so that theyinfiltrate the adjacent anatomic structures and pressurise them, endangering thereby health and even life of thediseased (Mah and Webster, 2001). Of a particular note, the fact that the pituitary gland is seated next to the opticalstructures enables macroprolactinomas to pressurise the optical nerve and/or the optical chiasm, so that somepatients may experience more or less pronounced visual field defects. The latter often represent the first symptom ofa macroprolactinoma presence.As compared to macroprolactinomas, the secretion activity of microprolactinomas is by far lower. Due to thehigh level of prolactin they synthesise and release, macroprolactinomas are featured by a distinctive clinicalpresentation (Asa, 1988; Levy and Lightman, 1993). In order to treat them, contemporary medicine mostly resorts todopamine agonists (DAs) as the first-line pharmacotherapy. However, microprolactinomas and macroprolactinomasdiffer in their sensitivity to such a treatment (Braucks et al, 2003). While microprolactinomas are only poorlyresponsive, a substantial reduction in prolactin level, but not in tumour size, can be seen in most patients diagnosedwith macroprolactinomas and taking Das. (Levy and Lightman, 1993). On top of dopamine agonists, contemporarymedicine makes use of microsurgery and radiotherapy (Horvath and Kovacs, 1992, Braucks et al, 2003).This study aims at demonstrating the efficiency of phytotherapy in macroprolactinoma downsizing andstrives to prove that pharmacoactive ingredients present in remedial plant mixtures are ultimately capable ofattaining tumour regression.
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Subjects and MethodsThe study was carried out within 2005 – 2010 timeframe and comprised a total of 32 patients, out of which21 (65.6%) women and 11 (34.4%) men, all of them being the citizens of currently independent states occupying theterritory of the former Yugoslavia (Bosnia and Herzegovina, Croatia, Serbia and Macedonia). The patients’ agespanned from 16 to 78 (average age, 40.7). Prior to PT commencement, the patients submitted medical recordsrevealing their diagnosis established based on the nuclear magnetic resonance imaging (NMRI) and/or computedtomography (CT) of the affected site, hormonal status and field-of-vision examination. These data served as thebaseline for comparison and follow-up of the PT efficiency.Throughout the study course, macroprolactinoma patients had been treated with three distinctive plantremedies (Preparations 1, 2 & 3). These preparations mutually differ in their composition and consist solely of
pounded herbs lacking any additives whatsoever. The constitutive plants are pounded to the standard degree (Lukić, 1993). Flowers, stalks and leaves were prepared using a number 6 sieve (rough cutting), roots and barks using a
number 3 sieve, and seeds and fruits using a number 2 sieve (precise cutting) (Pekić, 1983; Kovačević, 2000). These plant preparations are prepared and drunk in form of tea and have to be used on an everyday basis in line with thefollowing schedule: Preparation 1 at 7:00 am, Preparation 2 at 2:00 pm, and Preparation 3 at 7:00 pm. All of them areprepared in the same way, a single tea dose thereby calling for 1.5 g of the herbal mixture and 200 cm3 of water.Following the analysis of the PT efficiency in terms of tumour mass downsizing carried out on the wholestudy sample level, the subjects were divided into two groups.Group 1 (hereinafter referred to as: the PT only arm) consisted of 9 patients receiving only PT. Out of them,8(88.9%) were women and 1 (11.1%) was a man. They were aged 37.5 on the average (range, 20-70). Group 2(hereinafter referred to as: the DA & PT arm) consisted of 23 patients, in specific, 10 men (43.47%) and 13 women(56.53%) receiving PT in addition to their regular DA medication. The group in reference was aged 41.9 on theaverage (range, 16-78).Our next goal was to determine the manner in which the length of previous DA therapy affects PT outcomes.To that end, the members of the DA & PT arm were further subdivided into two subgroups based on the length of theirpre-PT DA therapy. Subgroup 2A embraced the patients previously treated with DAs for 8-26 months and consisted of19 patients, out of which 12 (63.1%) were women and 7 (36.9%) were men. The patients were aged 41.4 on theaverage, the youngest among them being 16 and the oldest one being 78. Prior to the PT launch, 4 of our studypatients had been treated with DAs for over 36 months (Subgroup 2B). This subgroup embraced 3 (75%) men andone (25%) woman at the average age of 44.7 (range, 22-59).Out of the entire study pool, 15 (46.8%) patients had experienced more or less severe pre-PT visualsymptoms arising on the grounds of compression of optical structures exerted by macroprolactinoma. Out of those, 8(53.3%) were of a female and 7(46.7%) of a male gender. These patients were aged 40 on the average (range, 18-59).Within the frame of the statistical analysis and outcome reporting, this patient subgroup was processed and presentedseparately.The comparison between the pre-PT and post-PT health statuses carried out throughout the follow-upperiod made use of the following key endpoint measures:1. Data on tumour size;2. Data on the state of the field-of-vision of the patients suffering from pre-PT visual field defects;3. Data on prolactin levels;4. Data on prior treatments;5. Data on PT length and side-effects.The obtained data served as the basis for mathematical-statistical analysis aiming at corroborating or refuting certainPT administration-related hypotheses. In order to obtain as reliable conclusions as possible, the credibility of theobtained data was analysed first; in further course, the analysis of data on tumour size prior to and following PT wascarried out in order to verify the PT efficiency. In pursue of this path, the hypothesis on the significance of differencesin pre-PT and post-PT tumour dimensions was tested at 5%-, 1%-, and 0.1%-significance levels; the significancethreshold of >5% was used only in cases of a scarce relevant information.In addition to the standard statistics, the testing of significance of the differences between the endpointmeasures obtained prior to and following phytotherapy employed the following non-parametric statistics: the pairedsample sign test, Wilcoxon sign-rank test, Mann-Whitney U-test and McNemar’s test.The statistical analysis was run through the following software:1. IBM SPSS Statistics 13.0 for Windows2. DATA ANALYSIS USING Microsoft EXCELThe results of the hypothesis accuracy testing shall be given not only in form of figures, but in form of graphs as well.
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Results As pointed out previously, data on the efficiency of the pituitary gland tumour phytotherapy (PT) came as aresult of a five-year follow-up of relevant endpoint measures obtained across the sample of 32 macroprolactinomapatients. In the pertaining diagrams and tables, the patients were assigned ordinal numbers spanning from 1 to 32,their sequence thereby matching the order of their applications. Within this particular study frame, the efficiencyanalyses were focused on changes in tumour size.
Analysis of changes in tumour size witnessed following PT as compared to the pre-PT status – the entire
patient sampleThe basic tumour size indicators obtained by virtue of descriptive statistics revealed significant changes inthe mean tumour size prior to and following PT.Prior to PT, the mean tumour size equalled to 22.00 mm; following PT, it decreased to 9.72 mm. This is to say that a56%-tumour downsizing was achieved. Based on the latter result, the assumed PT efficiency in tumour downsizingwas corroborated at the level of significance of 1%. The same was obtained using the 0.1%-significance merit.Graphical display of the results descriptive of differences in tumour sizes prior to and following PT, obtained on theentire sample level, is given in Diagram 1.
Group 1: PT only armFollowing the analysis of changes in tumour size witnessed across the entire study sample, the patients weredivided into 2 groups; in further course, the analyses of changes in tumour size were separately run across the PT only(Group 1) and the DA & PT arm (Group 2).Out of 32 participating patients, 9 gave up on DAs prior to PT and continued taking herbal remedies only (PTonly arm). The basic parameters descriptive of the tumour size, obtained by virtue of descriptive statistics, revealed asignificant difference in the mean tumour size prior to and following PT. Prior to PT, the mean tumour size equalled to20.11 mm; following PT, the mean tumour size decreased to 3.4 mm, meaning that an 83%-tumour downsizingultimately managed to be attained (Diagram 2).
Diagram 1
Note: During the course of PT female patients number 19 and 23 managed to conceive due to the decrease inprolactin levels, so the data on their tumour size are lacking. Therefore, these patients were excluded from thestatistical analysis. For the sake of further data processing, the sizes of their tumours were deemed to be equal to themean tumour size seen across their respective study groups (see Diagrams 1,3 and 4).
The statistical significance of the tumour mass downsizing seen following PT, as compared to the pre-PT state, wascorroborated at the level of significance of 5%.
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Diagram 2However, if tested at the significance level of 1%, the difference in pre- and post-PT tumour sizes became statisticallyinsignificant.
Group 2: DA & PT armDA & PT arm was constituted of 23 patients simultaneously receiving phytotherapy and dopamine agonists.In this patient group, the basic parameters descriptive of tumour size, obtained by virtue of descriptive statistics, alsorevealed a significant difference in the mean tumour size prior to and following PT. The mean pre- and post-PTtumour sizes registered across these patients were 22.74 mm and 11.93 mm, respectively (Diagram 3); in otherwords, a 48%-tumour downsizing was achieved. The statistical significance of the difference in tumour size prior toand post the combined treatment was corroborated both at the level of significance of 1% and at the level ofsignificance of 0.1 %.
Diagram 3
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The comparison of tumour downsizing attained in Group 1 vs Group 2Based on the data on mean tumour sizes and other statistical indicators, a comparative analysis of data ontumour sizes registered in PT only and DA & PT arms was carried out. This analysis aimed at comparing the outcomesof the two different treatments. When tested for their individual significance at 5%-significance level, the differencesin mean tumour sizes were proven to be insignificant. Comparative analysis of mean tumour sizes registeredfollowing PT only and following the concomitant DA and PT treatment confirmed the anticipated efficiency of bothtreatment modalities. The testing ran at the level of significance of 5% revealed the phytomonotherapy, as well as DA& PT combination therapy, to be capable of statistically significantly reducing the size of the tumour, which canjustifiably be attributed to PT administration. Nevertheless, the same failed to be proven at the significance level of1%, suggesting that a more reliable comparative analysis would call for larger patient samples.
Subgroup 2A - DA & PT arm: Patients previously receiving DAs for 8 – 26 monthsThe next step taken during the course of the study was to verify the impact of previous DA treatment on PToutcomes. To that goal, the total of 23 DA & PT patients was divided into two subgroups: Subgroup 2A, consisting of19 patients previously receiving DAs for 8 to 26 months, and Subgroup 2B, consisting of 4 patients previouslyreceiving DAs longer than 36 months.In Subgroup 2A, whose members had received DAs for 8 to 26 months prior to the PT launch, statistically significantdifferences in mean tumour sizes prior to and following the combined therapy were revealed. Prior to the PTcommencement, the mean tumour size seen across these patients equalled to 19.9 mm, as compared to 8.9 mmmeasured following the PT completion, indicating a 56%-downsizing of the tumour mass. The difference in pre-PTand post-PT mean tumour sizes remained significant at 5%-, 1%-, and 0.1%-significance levels. The results aregraphically represented by Diagram 4.
Subgroup 2B: DA & PT arm: Patients previously receiving DAs > 36 monthsPrior to the PT commencement, 4 of the study subjects had taken DAs for longer than 36 months. Prior tothe PT implementation, the mean size of the tumour equalled to 36.0 mm; following the combined DA & PT therapy,the mean size of the tumour was reduced to 26.0 mm (Diagram 5), hence by 28%. Statistical indicators corroborated
Diagram 4
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Diagram 5
that certain changes in tumour size did occur, but the difference in tumour sizes prior to and following the combinedtherapy lacked statistical significance, at least at the level of significance of 5%. The results obtained in this patientsubgroup might be indicative of an unfavourable impact of a multiyear DA therapy reflecting in the PT efficiencyhindrance. However, given the fact that the subgroup in reference was composed of no more than 4 patients, oneshould not jump to conclusions, but rather provide for a more representative future patient sample. Nevertheless, it isto be reiterated that, even though insignificant, certain tumour regression was noted in these cases as well.
visual field defect (VFD) and the size of the tumourVFD comes as a result of tumour compression exerted on optical structures. The results displayed belowprove the favourable impact of phytotherapy on tumour downsizing.The impact of PT on VFD was not analysed in all of the 32 patients, but only in those 15 that had experienced visionproblems prior to the PT commencement (Table 1).
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Table 1 VFD status prior to and following PT
Following PT, in 9 (60%) out of these 15 patients, the vision was restored to normal. In these patients, thereduction in tumour size seen following PT spanned from 45% to 100%. In 6 (40%) patients in whom a VFD persisteddespite of PT, the attained tumour downsizing ranged from 0 % to 35% (marked with black dots in Diagram 6). Ascan be seen from the data, in patients lacking a VFD following PT, the reduction in tumour size was far greater than inthose having a persistent, PT-irresponsive VFD (statistical significance of the difference in tumour downsizing provenat the level of significance of 5%, but not at the level of significance of 1%).
Diagram 6
Patient’s ordinal
number
VFD prior to PT VFD following
PT
1 + -
3 + -
4 + +*
10 + -
11 + -
12 + +*
16 + -
17 + +
20 + -
22 + -
24 + +
26 + -
29 + -
30 + +
32 + +
Abbreviations:
PT phytotherapy
VFD visual field defect
( + ) VFD present
( - ) VFD lacking
+* permanent VFD
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Statistical analyses proved a close correlation between the tumour downsizing and the VFD status. Duly chosen testsexamining the interrelation between these two variables ran at the level of significance of 0.1%, definitely provedtheir interdependence.
DiscussionIn addition to more or less striking side-effects, among them a higher risk of developing heart fibrosisserving the EMEA as the grounds for limiting the maximal permissible daily DA doses (EMEA; Europe, 2011), DAtreatment also leads to changes in tumour structure. In a number of bromocriptine-treated patients, intra-tumourbleedings and cyst formation have been seen. All DAs, bromocriptine in particular, enhance tumour fibrosis, which
hinders surgery and narrows its scope to a substantial degree (Pehaček and Sajdl, 1990). Given the fact that previous long-term DA treatment diminished PT efficiency in our patients as well, it is safe to say that, when consideringtreatment options, PT should be chosen over DAs. The fact that patients undergoing PT for 2-41 months failed toexperience any side-effects whatsoever throughout the PT course regardless of its length further supports the aboveposition statement. The fact that two female subjects (allocated ordinal numbers 19 and 23) got pregnant while on PTalso speaks in favour of PT safety. Both of them were originally assigned to the DA & PT arm, but decided to quit DAsonce they got pregnant and stuck to PT, which went smoothly throughout the entire pregnancy. Following the DAcessation, PT was recommended to be continued due to pregnancy-related hyperestrogenism and threateningoestrogen-enhanced tumour growth (Mah and Webster, 2001).In patients responding to PT, tumour downsizing was witnessed within 6 months of the PT commencement, the bestresults thereby being obtained in patients continuously taking herbal remedies for 10 or more months.
1. The impact of PT on macroprolactinoma sizeThe subjects included into this study had unanimously started their macroprolactinoma treatments with themost commonly employed dopamine agonist bromocriptine. Nowadays, medical research is designed so as to providethe intention-to-treat population with the “gold standard” therapy for the condition under investigation (Geddes andCipriani, 2004). Respecting that principle, our DA-treated patients also continued taking DAs concurrently with PT.Mono-PT was administered only to patients forced to give up on DAs due to severe side-effects. Any other approach tothis study would jeopardise its ethics and integrity. Nevertheless, this line of approach had a substantial impact on ourstudy design and resulted in the formation of several study groups/subgroups. Based on the aforementioned, theresearchers were given the opportunity not only to observe the impact of PT on tumour size across the entire (32-)patient sample, but to compare the results obtained with PT only (9-patient) arm and DA & PT (23-patient) arm.On top of medication, a total of 15 study patients had surgery prior to the PT commencement. The surgeryallowed for the removal of almost the entire tumour mass, as well as for the subsequent depressurisation of theadjacent structures and temporary alleviation of macroprolactinoma-related symptoms. However, none of thepatients had his/her tumour totally removed, so that in time the residual tumour cells served as the grounds formacroprolactinoma re-formation. In four of the operated patients, the surgery failed even twice. Medical recordsobtained prior to the PT commencement clearly showed that each and every study subject had an optimal treatmentdelivered by their attending healthcare facilities, so that, as far as contemporary medicine is concerned, the bestpossible care had been provided.The herbal remedy efficiency analysis carried out on the entire sample level and particularly the resultsobtained across the PT only arm have clearly demonstrated the favourable impact of herbal remedies on tumour massreduction. The results attained across the PT only arm represent the most important outcome of this study, since theyshowed beyond any doubt that tumour mass reduction and even restoration to health (patients Nos 1, 2, and 25) canbe achieved in those suffering from macroprolactinomas solely by virtue of herbal remedy use, allowing for thepossibility of PT implementation as the first-line macroprolactinoma treatment. A substantial, however less strikingeffect in terms of tumour mass reduction was also achieved in the DA & PT arm. Given that the statistical analysisrevealed no significant pre-PT differences between the mean sizes of the tumours seen in patients who gave up ontheir medication as compared to those still taking DAs, it became obvious that pharmacotherapy had no significantimpact on tumour size, so that the substantial tumour downsizing can mostly be attributed to PT implementation.This is the very first time that a study actually managed to firmly prove the efficiency of herbal remedies inmacroprolactinoma downsizing; namely, at least to our knowledge, similar studies have never been published before.
2. Impact of the previous DA treatment on the PT outcomeFar better results obtained with the PT only arm (average tumour downsizing of 83%) as compared to theDA & PT arm (average tumour downsizing of 48%), suggest that, when it comes to tumour mass reduction, earlier DAtreatment might decrease the PT efficiency. Further analysis of the results obtained in DA-treated patients (Subgroups2A and 2B) led one to conclude that therapeutic effectiveness of herbal remedies weakens as DA administration goes
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on, so that the poorest results were obtained in patients treated with DAs for longer than 3 years; the average tumourmass reduction seen across these patients (56% in Subgroup 2A and 28% in Subgroup 2B) supports this standing. Theanalysis of the study data indicated that prior DA treatment interferes with signalling paths utilised bypharmacoactive plant ingredients, so that the PT efficiency declines with DA treatment duration. Based on theaforementioned, it can also be clearly understood that tumour downsizing, coming as a result of the pharmacoactiveplant ingredients’ administration, is not mediated by D2 receptors.This article brings the report on favourable effects of herbal preparation administration. Nevertheless, theidentification of individual pharmacologically active components is associated with a number of problems. Themajority of plants composing the herbal preparations administered to macroprolactinoma patients are aromaticplants basically composed of ethereal oils; it has been shown without a shred of doubt that the pharmacoactivity ofthese oils gives rise to PT efficiency. However, given that these herbal preparations come in form of infusions, oneshould take into account that only some of their hydrophobic ingredients get to pass into the water solution, togetherwith a number of other secondary metabolites. In line with the foregoing, it is reasonable to assume thatpharmacological activity of aromatic plants does not depend solely on the presence and efficiency of ethereal oils, butalso on the activity of other ingredients constituting the plant mixtures; for that matter, the possibility of theirsynergistic effect can not be ruled out.One can also expect to come across a number of difficulties when trying to identify active ingredients ofethereal oils, since the activity of the latter actually represents a “combined effort” of all ingredients. Therefore, the
pharmacoactivity of aromatic plants differs from that of ethereal oils isolated from such plants (Kovačević, 2000). Dueto the aforementioned, the pharmacological activity of ethereal oils is commonly defined for the oil “in toto” ratherthan for its individual components whose pharmacokinetics and metabolism are often very hard or virtuallyimpossible to track. Consequently, most studies akin to our actually report on the effects of PT administration andmake ex iuvantibus judgements.Elucidation of the exact action mechanism through which active substances present in herbal mixtures used withinthis study take their course of action and eventually manage to downsize the tumour shall contribute to betterunderstanding of the development of tumours of neurohormonal aetiology.
3. PT impact on visual field defect ( VFD )In 15 study participants, the size of the tumour and the direction of its growth finally caused a visual field defect(VFD). The subjects had been subjected to occasional MRI or CT controls, most often scheduled every 6 months; inthose who experienced tumour regression, clearance of sight symptoms posed as the first sign of tumour downsizing,later corroborated by virtue of the pituitary gland diagnostic imaging. In addition to optical structures’depressurisation, a smaller degree of sinus involvement was established in patients having their tumours penetratedinto the cavernous sinuses. The macroprolactinoma invasion into the cavernous sinuses speaks of its aggressiveness,forecasts a poor prognosis and makes the tumour virtually inoperable (Asa, 1988). In patients whose tumours becamesubstantially smaller, full cavernous sinus riddance from the tumour was noted, making the chances for a successfulsurgery markedly higher. In these patients, vision recovery took place within 6 months of the PT commencement. Ofnote, even prior to PT, two of our patients had been diagnosed with a permanent visual field defect, so that muchcould not be done anyway.The results brought by this article demonstrate the efficiency of PT in macroprolactinoma downsizing, thereforeopening the prospects for the following:
 Non-surgical treatment and consequential avoidance of risks associated with surgical procedures;
 Adjuvant therapy, to be administered to those whose tumour is inoperable either due to its size or dueto the position of its seat, as well as to those who refuse to undergo surgery or can not have it due tocontraindications;
 Administration of phytotherapy to the effect of preoperative tumour downsizing, allowing for thepossibility of a more effective subsequent surgery;
 The possibility of a preventative PT, to be carried out in pregnant women suffering frommacroprolactinoma and refusing DAs during pregnancy.
Conclusion
Our previous study (Trogrlić et al, awaiting publication) showed the usefulness of PT in macroprolactionoma secretion activity control. The results of this study demonstrated its additional efficiency in tumour downsizing. Theoutcomes seen across patients whose tumours became virtually undetectable following PT clearly demonstrate thatsome of the patients might be restored to health solely by virtue of phytotherapy administration.
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